Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

LAU-0901 is a platelet-activating factor (PAF) receptor antagonist.1,2 In vivo, LAU-0901 (30, 60, and 90 mg/kg) reduces infarct volume and improves neurological function in a rat model of cerebral ischemia induced by middle cerebral artery occlusion (MCAO).1 It also reduces microglial infiltration and increases astrocytic and neuronal survival in the same model.2 LAU-0901 (30 mg/kg) alone, or in combination with atorvastatin (Item No. 10453), reduces tumor growth in a U87MG glioblastoma mouse orthotopic tumor model.3
WARNING This product is not for human or veterinary use.
1. LAU-
2. Superior neuroprotective efficacy of LAU-
3. Combined therapy with avastin, a PAF receptor antagonist and a lipid mediator inhibited glioblastoma tumor growth. Front. Pharmacol. 12, 746470 (2021).